Correction: Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation - Takeaways - MDSpire

Correction: Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation

  • By

  • Yasuyuki Miyake

  • Shoichi Iriguchi

  • Ai Kawana-Tachikawa

  • Shuichi Kitayama

  • Eri Imai

  • Kahoru Taya

  • Hiroshi Ishii

  • Tomoyuki Miura

  • Hiromi Sakawaki

  • Tetsuro Matano

  • Shin Kaneko

  • May 27, 2026

  • 0 min

Share

  • 1

    A correction was issued regarding the funding statement in a study on iPSC-derived innate-like T cells.

  • 2

    The study demonstrated the short-term safety and feasibility of autologous transplantation in a non-human primate model.

  • 3

    The authors of the study include Miyake Y, Iriguchi S, Kawana-Tachikawa A, and others.

  • 4

    The correct funding statement includes an additional grant number: JP25fk0410060.

  • 5

    The original article was published in Frontiers in Immunology in 2026.

Original Source(s)

Correction: Non-human primate preclinical model revealed the feasibility and short-term safety of iPSC-derived innate-like T cells in autologous transplantation

  • by Yasuyuki Miyake, Shoichi Iriguchi, Ai Kawana-Tachikawa, Shuichi Kitayama, Eri Imai, Kahoru Taya, Hiroshi Ishii, Tomoyuki Miura, Hiromi Sakawaki, Tetsuro Matano, Shin Kaneko

  • May 27, 2026

Related Content

The predictive value of platelet-to-high density lipoprotein cholesterol ratio and white blood cell-to-mean platelet volume ratio for coronary artery disease risk in STEMI patients

Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms